Johan from New Zealand

Registered at the short selling broker eToro, 5 minutes ago.

» Try eToro you too
67% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

GlaxoSmithKline Plc (GSK) shares information

GSK Plc – ADR


24h Change

0.91 %

GSK

Live rate: Market closed

Stock data per Friday 2 Dec, 2022

GSK
NEW YORK STOCK EXCHANGE INC.
35.03
34.93
35.35
0.32 (+ 0.91%)
US Market is closed

Live Stock price in graph for GSK Plc – ADR (GSK)

  • Latest Volume

    4,894,069 (26.59 %)

  • Volume prev. day

    3,865,947

  • Avg. daily volume

    5,309,174

  • Market cap

    71,890,447,943

  • P/E ratio

    5.15

  • Today high

    35.47 USD

  • Today low

    34.91 USD

  • 52 week high

    57.03 USD

  • 52 week low

    28.19 USD

  • YTD Change

    n/a

Quick links

 

Latest news about GSK Plc – ADR

Below you can find the most recent news posts about GSK Plc – ADR, primarily from US and UK based news sources.

GSK Jemperli shows survival benefit in uterus cancer, meets main goal of phase 3 trial

Friday, 2 December 2022, 11:40:38
GSK (GSK) said its medicine Jemperli (dostarlimab) met the main goal of progression-free survival ((PFS)) in patients with primary advanced or recurrent endometrial cancer in a phase…
— Seeking Alpha


GSK bone marrow cancer therapy momelotinib gets review in EU

Friday, 2 December 2022, 11:03:45
The European Medicines Agency ((EMA)) accepted for review GSK”s (GSK) application seeking approval of oral therapy momelotinib to treat myelofibrosis.The British pharma giant said…
— Seeking Alpha


GlaxoSmithKline PT Lowered to GBP15.50 at Citi

Friday, 2 December 2022, 10:20:09
https://www.investing.com/news/pro/glaxosmithkline-pt-lowered-to-gbp1550-at-citi-432SI-2956159
— Investing.com


GSK makes headway with two cancer drugs after double-barrelled setback last month

Friday, 2 December 2022, 10:12:39
GlaxoSmithKline (GSK) is making “significant” headway with two of its cancer drugs, following a double-barrelled setback in its oncology efforts last month. The British pharmaceutical giant’s bone marrow cancer treatment Momelotinib this morning received marketing approval from the European Medicines Agency, following an application to the FDA in the US in August. If approved by […] The post GSK makes headway with two cancer drugs after double-barrelled setback last month appeared first on CityAM .
— City AM


GSK :EMA Accepts Marketing Authorization Application For Momelotinib For Rare Blood Cancer Treatment

Friday, 2 December 2022, 09:16:00
LONDON (dpa-AFX) – GSK plc (GSK.L, GSK) said Friday that the European Medicines Agency has accepted the marketing authorization application for momelotinib for the treatment of myelofibrosis.The a…
— Finanz Nachrichten


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have GSK available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.